Brought to you by 
Medicago, Mitsubishi Tanabe team up for rotavirus and other vaccines using VLP technology
08 Jul 2013
Executive Summary
Medicago Inc. (developing virus-like particle (VLP) vaccines and manufacturing technologies) and Mitsubishi Tanabe Pharma Corp. are collaborating on the development and commercialization of at least three new vaccines using Medicago’s VLP technology.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medicago, Mitsubishi Tanabe team up for rotavirus and other vaccines using VLP technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice